The European Medicines Agency Review of Eltrombopag (revolade) for the Treatment of Adult Chronic Immune (idiopathic) Thrombocytopenic Purpura: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

BackgroundChronic idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by autoantibodyinduced platelet destruction and reduced platelet production, leading to a low peripheral blood platelet count.The clinical hallmark of the disease is an increased, pathological tendency to bleed either spontaneously or after minimal trauma.Disease management decisions in patients with chronic ITP are based primarily on platelet count and severity of bleeding.The goal of treatment is to elevate platelet counts to a safe range (≥50¥10 9 /L to The European Medicines Agency review of eltrombopag (Revolade) for the treatment of adult chronic immune (idiopathic)